Investigating the clinical potential for 14-3-3 zeta protein to serve as a biomarker for epithelial ovarian cancer

Ioannis Hatzipetros, Peter Gocze, Tamas Koszegi, Akos Jaray, Laszlo Szereday, Beata Polgar, Nelli Farkas, Balint Farkas

Research output: Contribution to journalArticle

10 Citations (Scopus)


Objective. Recently, 14-3-3 zeta protein was identified as a potential serum biomarker of epithelial ovarian cancer (EOC). The goal of this study was to investigate the clinical potential of 14-3-3 zeta protein for monitoring EOC progression compared with CA-125 and HE4. Design. Prospective follow-up study. Setting. University of Pecs Medical Center Department of Obstetrics and Gynecology/Oncology (Pecs, Hungary). Population. Thirteen EOC patients with advanced stage (FIGO IIb-IIIc) epithelial ovarian cancer that underwent radical surgery and received six consecutive cycles of first line chemotherapy (paclitaxel, carboplatin) in 21-day intervals. Methods. Pre- and post-chemotherapy computed tomography (CT) scans were performed. Serum levels of CA-125, HE4, and 14-3-3 zeta protein were detected by enzyme-linked immunosorbent assay (ELISA) and quantitative electrochemiluminescence assay (ECLIA). Main outcome measures. Serum levels of CA-125, HE4, and 14-3-3 zeta protein, as well as lesion size according to pre- and post-chemotherapy CT scans. Results: Serum levels of CA-125 and HE4 were found to significantly decrease following chemotherapy, and this was consistent with the decrease in lesion size detected post-chemotherapy. In contrast, 14-3-3 zeta protein levels did not significantly differ in healthy postmenopausal patients versus EOC patients. Conclusions: Determination of CA-125 and HE4 serum levels for the determination of the risk of ovarian malignancy algorithm (ROMA) represents a useful tool for the prediction of chemotherapy efficacy for EOC patients. However, levels of 14-3-3 zeta protein were not found to vary significantly as a consequence of treatment. Therefore we question if 14-3-3 zeta protein is a reliable biomarker, which correlates with the clinical behavior of EOC.

Original languageEnglish
Article number79
JournalJournal of Ovarian Research
Issue number1
Publication statusPublished - Nov 19 2013



  • 14-3-3 Zeta protein
  • CA-125
  • Chemotherapy
  • Epithelial ovarian cancer
  • HE-4
  • ROMA

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Cite this